DCOYHealthcare · Biotechnology

DCOY Stock Forecast: Decoy Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Sept 2026

$2.63

−2.23% on the day

The 1 Wall Street analysts covering Decoy Therapeutics, Inc. hold a median 12-month price target of $30 — +1040.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 7 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$1.8M

Ticker Nerd rank

14 / 100

Median analyst target

$30

Analysts covering

Revenue$0.0

Operating income−$2.4M

Net income−$2.4M

Free cash flow−$2.7M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−13.8%

−33.1%

YTD

−66.2%

−95.3%

From 52W high

−96.1%

From 52W low

0.0%

$68

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

DCOY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Decoy Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026

14 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Volatility

Growth

Revisions

Issuance

Momentum

Quality

Value

Size (99): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DCOY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DCOY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $30Median $30High $30

The green dot is the last close — the median target sits +1040.7% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
23 Jan 2026	Ladenburg Thalmann	Initiates	Buy	$2.50
11 Mar 2022	HC Wainwright & Co.	Maintains	Buy	$5.00 → $4.00
25 Aug 2021	HC Wainwright & Co.	Initiates	Buy	—
16 June 2020	Benchmark	Initiates	Speculative Buy	—
27 Apr 2020	Ladenburg Thalmann	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCOY appears on the weeks it earns a place.

Performance

DCOY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Sept 2026, Decoy Therapeutics, Inc. returned −95.3% against +19.4% for the S&P 500, dividends included.

DCOY vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DCOY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Decoy Therapeutics, Inc. (DCOY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 7.7×
Price / book: 0.3×
EV / EBITDA: 1.1×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: −1055.8%
Net margin: 0.0%

Returns & dividend

Return on equity: −827.8%
Return on assets: −73.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Decoy Therapeutics, Inc. (DCOY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Decoy Therapeutics, Inc. has a market value of $1.8M and an enterprise value of −$6.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$14.4M.
Free cash flow in the twelve months to 30 June 2026: −$8.9M.
Shares outstanding: 531,968.
Trailing P/E: 0.0×; forward P/E: −0.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Decoy Therapeutics, Inc. employs 11 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

DCOY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
DCOYDecoy Therapeutics, Inc.	$1.8M	14
CMNDClearmind Medicine, Inc.	$1.7M	9
SLXNSilexion Therapeutics Corp.	$2.0M	56
BBLGBone Biologics Corp.	$1.6M	28
VRAXVirax Biolabs Group Ltd.	$2.1M	15
OGENOragenics, Inc.	$2.2M	10
HELPCybin, Inc.	$1.4M	42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Decoy Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DCOY news & analysis

Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Newsfile Corp · 8 Sept 2026neutral

Decoy Therapeutics announced that its Chief Executive Officer, Rick Pierce, will present a corporate overview and hold one-on-one investor meetings at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026 in New York City.

Why it matters — A DCOY watcher would care because the company's CEO will gain exposure to investors at a major life sciences conference, offering an opportunity for increased visibility.

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

PRNewsWire · 3 Aug 2026positive

Decoy Therapeutics announced the expansion of its intellectual property portfolio, which now spans seven patent families and 19 pending applications across seven jurisdictions. The portfolio covers antiviral peptide conjugates, methods of manufacture, formulations, and the company's IMP³ACT design platform for its Designable Multi-Antivirals.

Why it matters — A broader and more extensive IP portfolio could strengthen Decoy's protection of its D-MAV platform and pipeline assets.

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

PRNewsWire · 27 July 2026positive

Decoy Therapeutics announced that one of its D-MAV candidates demonstrated in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute, validating its D-MAV platform and expanding into filovirus pandemic preparedness.

Why it matters — A DCOY watcher would care because this news validates the D-MAV platform's cross-viral family fusion inhibition capability and opens a new program addressing high-consequence global health threats.

FAQ

Frequently asked questions about DCOY stock

What is the DCOY stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Decoy Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DCOY stock a buy right now?

Of the 1 analysts covering Decoy Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Decoy Therapeutics, Inc. 14 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DCOY?

As at 7 Sept 2026, Decoy Therapeutics, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

Will DCOY stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1040.7% from the last close, and Ticker Nerd's factor model ranks Decoy Therapeutics, Inc. 14 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DCOY stock forecast for 2030?

No analyst covering Decoy Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCOY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has DCOY stock performed over the past year?

Decoy Therapeutics, Inc. returned -95.3% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Decoy Therapeutics, Inc. do?

Decoy Therapeutics Inc. is a pre-clinical biotechnology company focused on discovering and developing peptide conjugate therapeutics.

What is the latest news on DCOY?

The most recent item we track (Newsfile Corp, 8 Sept 2026): "Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference". Decoy Therapeutics announced that its Chief Executive Officer, Rick Pierce, will present a corporate overview and hold one-on-one investor meetings at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026 in New York City.

Company

About Decoy Therapeutics, Inc.

Decoy Therapeutics Inc. is a pre-clinical biotechnology company focused on discovering and developing peptide conjugate therapeutics. Its core work centers on the IMP3ACT platform, which uses machine learning, artificial intelligence, and rapid synthesis methods to design and manufacture peptide-based drug candidates with improved targeting and development efficiency. The company’s current programs emphasize infectious diseases, with a particular focus on respiratory viruses, as well as oncology and other high-unmet-need areas. Decoy Therapeutics is developing Designable Multi-Antivirals, a class of antiviral candidates intended to address shared viral mechanisms across multiple virus families. The company also maintains a broader pipeline that includes legacy therapeutic assets alongside its newer antiviral efforts. Headquartered in Houston, Texas, Decoy Therapeutics operates as a research-driven biotechnology business aimed at advancing novel therapeutic platforms for difficult-to-treat diseases.

CEO Mr. Frederick E. Pierce II · 11 employees · United States · https://decoytx.com